• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

Safety

  • Print
  • Share
  • E-mail

Emend (aprepitant) capsules

Detailed View: Safety Labeling Changes Approved By FDA Center for Drug Evaluation and Research (CDER) – March 2010

 

Summary View

 

ADVERSE REACTIONS

Clinical Trials Experience
  • section (including Table 2) was updated to include the adverse experience data from the sponsor's completed postmarketing study.

CLINICAL STUDIES

Post-Marketing Trial
  • Entire Section Updated
  • In a postmarketing, multicenter, randomized, double-blind, parallel-group, clinical study in 848 cancer patients, the aprepitant regimen (N=430) was compared with a standard of care therapy (N=418) in patients receiving a moderately emetogenic chemotherapy regimen that included...